Back to results
US 12,594,253 B2Granted
HIV inhibitors
AssigneeMax-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V.
InventorsMarina V. Rodnina-Wintermeyer, Natalia Korniy, Ekaterina Samatova, Frank Peske
Life of this patent
Estimating the term…
Abstract
The present invention relates to a compound comprising of the nucleotide sequence UAA or TAA and a binding site for the covalent attachment of leucine (Leu), wherein said compound is recognized by a ribosome, for use in medicine.
Claims3
A method of treating or ameliorating an infection with HIV virus, with SIV virus, with an Alphavirus and/or AIDS in a subject, said method comprising administering a tRNALeu(UAA) which
- (a) differs from any human wild-type tRNALeu(UAA), by at least one up to ten mutations of the base sequence in a stem region of the tRNA, wherein each of said mutations is a substitution or deletion;
- and/or
- (b) comprises at least one modification of a ribose and/or of a phosphate, wherein said modification is selected from 2′-O-methyl, 2′-deoxy, 2′-fluoro, thiophosphate, LNA, and PNA.
Dependencies are inferred from the claim text.